Kymera Therapeutics annual working capital
2019
2020
2021
2022
2023
2024
2025
Kymera Therapeutics Working Capital Growth & History (KYMR)
Kymera Therapeutics's working capital was $788.0M for fiscal 2025.
View full Kymera Therapeutics company overviewKymera Therapeutics annual working capital history
| Fiscal year | Period ended | Working capital | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $788.0M | $345.5M | +78.08% |
| 2024 | 2024-12-31 | $442.5M | $122.9M | +38.44% |
| 2023 | 2023-12-31 | $319.6M | −$28.4M | −8.17% |
| 2022 | 2022-12-31 | $348.1M | −$10.7M | −2.97% |
| 2021 | 2021-12-31 | $358.7M | $167.0M | +87.11% |
| 2020 | 2020-12-31 | $191.7M | $133.4M | +229.00% |
| 2019 | 2019-12-31 | $58.3M | — | — |
Kymera Therapeutics quarterly working capital
Q4.19
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Working capital | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $665.9M | $25.2M | +3.93% |
| Q1 2026 | 2026-03-31 | $614.8M | $172.8M | +39.10% |
| Q4 2025 | 2025-12-31 | $788.0M | $345.5M | +78.08% |
| Q3 2025 | 2025-09-30 | $456.7M | −$45.5M | −9.05% |
| Q2 2025 | 2025-06-30 | $640.8M | $177.5M | +38.32% |
| Q1 2025 | 2025-03-31 | $442.0M | −$39.2M | −8.14% |
| Q4 2024 | 2024-12-31 | $442.5M | $122.9M | +38.44% |
| Q3 2024 | 2024-09-30 | $502.2M | $189.7M | +60.68% |
| Q2 2024 | 2024-06-30 | $463.3M | $132.5M | +40.04% |
| Q1 2024 | 2024-03-31 | $481.1M | $131.5M | +37.61% |
| Q4 2023 | 2023-12-31 | $319.6M | −$28.4M | −8.17% |
| Q3 2023 | 2023-09-30 | $312.5M | −$90.4M | −22.43% |
| Q2 2023 | 2023-06-30 | $330.8M | $15.5M | +4.93% |
| Q1 2023 | 2023-03-31 | $349.6M | $6.6M | +1.92% |
| Q4 2022 | 2022-12-31 | $348.1M | −$10.7M | −2.97% |
| Q3 2022 | 2022-09-30 | $402.9M | −$46.3M | −10.32% |
| Q2 2022 | 2022-06-30 | $315.3M | $59.1M | +23.09% |
| Q1 2022 | 2022-03-31 | $343.0M | $112.4M | +48.73% |
| Q4 2021 | 2021-12-31 | $358.7M | $167.0M | +87.11% |
| Q3 2021 | 2021-09-30 | $449.2M | $259.2M | +136.34% |
| Q2 2021 | 2021-06-30 | $256.1M | — | — |
| Q1 2021 | 2021-03-31 | $230.7M | — | — |
| Q4 2020 | 2020-12-31 | $191.7M | $133.4M | +229.00% |
| Q3 2020 | 2020-09-30 | $190.1M | — | — |
| Q4 2019 | 2019-12-31 | $58.3M | — | — |
Kymera Therapeutics working capital trends
Over the last five fiscal years, Kymera Therapeutics's working capital increased from $191.7M to $788.0M, a change of $596.3M. The latest reported quarter, Q2 2026, shows $665.9M.
About the metric
What working capital means
Working capital is the difference between current assets and current liabilities. It provides a snapshot of short-term operating liquidity, although negative working capital can be normal for some business models and the measure is often not meaningful for banks.
Calculation and source
How working capital is calculated
TickerStat calculates working capital as reported current assets minus reported current liabilities at the same balance-sheet date. Missing current classifications are not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kymera Therapeutics source filings ↗Community posts
Kymera reports early human results for oral IRF5 drug
Kymera ($KYMR) reported results from its first human study of KT-579, an experimental oral medicine targeting the immune regulator IRF5. In healthy volunteers receiving repeated doses, median blood IRF5 reductions reached at least 90% acros ...
